Sionna Therapeutics (SION) Stock Price, News & Analysis

Company Overview

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape. This modular design allows the company to rapidly iterate and customize mRNA constructs according to disease-specific biology and dosing requirements. Early preclinical results have demonstrated robust in vivo expression and favorable safety profiles, underpinning the advancement of multiple candidate programs toward clinical evaluation.

Headquartered in Vancouver, Canada, Sionna Therapeutics maintains additional research and development operations in the San Francisco Bay Area. Since its founding by a team of experienced biotech entrepreneurs and drug development veterans, the company has built a multidisciplinary leadership group with deep expertise in RNA chemistry, translational biology and clinical execution. Through collaborations with academic centers and contract development organizations, Sionna is positioning its pipeline for first-in-human studies and eventual commercialization partnerships.

With a commitment to expanding the reach of RNA medicines, Sionna continues to refine its platform and advance its lead candidates through regulatory milestones. The company’s research efforts are underpinned by a vision to deliver durable, precision-targeted treatments that address unmet needs in cancer and autoimmune diseases, while setting new standards for safety and efficacy in the rapidly evolving field of RNA therapeutics.

Key Stats

• Today's Range: $38.65 to $41.80
• 50-Day Range: $34.40 to $45.95
• 52-Week Range: $12.42 to $48.44
• Volume: 236,910 shs
• Average Volume: 346,388 shs
• Market Capitalization: $1.89 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $53.22
• Consensus Rating: Moderate Buy

Sionna Therapeutics Stock Analysis - MarketRank™

Sionna Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 445th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Sionna Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 3 strong buy ratings, 7 buy ratings, 1 hold rating, and 2 sell ratings.

Upside Potential

Sionna Therapeutics has a consensus price target of $53.22, representing about 28.9% upside from its current price of $41.28.

Amount of Analyst Coverage

Sionna Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sionna Therapeutics are expected to grow in the coming year, from ($2.57) to ($2.48) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sionna Therapeutics is -21.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sionna Therapeutics is -21.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sionna Therapeutics has a P/B Ratio of 6.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.75% of the float of Sionna Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Sionna Therapeutics has a short interest ratio ("days to cover") of 9.29.

Change versus previous month

Short interest in Sionna Therapeutics has recently increased by 11.33%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sionna Therapeutics does not currently pay a dividend.

Dividend Growth

Sionna Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.10

News Sentiment

Sionna Therapeutics has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Sionna Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for SION on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Sionna Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Sionna Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $77,562,902.00 in company stock.

Percentage Held by Insiders

3.90% of the stock of Sionna Therapeutics is held by insiders.

Percentage Held by Institutions

Sionna Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 5/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SION
• Previous Symbol: NASDAQ:SION
• CIK: 2036042
• Web: N/A
• Phone: (617) 819-2020
• Fax: N/A
• Employees: 35
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Sionna Therapeutics: $53.22
• High Price Target: $63.00
• Low Price Target: $24.00
• Potential Upside/Downside: +27.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.85
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.93)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$75.27 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -27.31%
• Return on Assets: -25.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 22.60
• Quick Ratio: 22.60

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.38 per share
• Price / Book: 6.54

Miscellaneous

• Outstanding Shares: 45,150,000
• Free Float: 43,389,000
• Market Cap: $1.89 billion
• Optionable: N/A
• Beta: 1.35